Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Intangibles for 6 consecutive years, with $13.7 million as the latest value for Q1 2026.

  • For Q1 2026, Intangibles fell 35.4% year-over-year to $13.7 million; the TTM value through Mar 2026 reached $13.7 million, down 35.4%, while the annual FY2025 figure was $14.3 million, 34.9% down from the prior year.
  • Intangibles hit $13.7 million in Q1 2026 for Barinthus Biotherapeutics, down from $14.3 million in the prior quarter.
  • Across five years, Intangibles topped out at $30.6 million in Q1 2022 and bottomed at $13.7 million in Q1 2026.
  • Average Intangibles over 5 years is $23.5 million, with a median of $24.3 million recorded in 2024.
  • Year-over-year, Intangibles decreased 10.06% in 2022 and then crashed 35.4% in 2026.
  • Barinthus Biotherapeutics' Intangibles stood at $28.3 million in 2022, then fell by 11.18% to $25.1 million in 2023, then fell by 12.59% to $21.9 million in 2024, then plummeted by 34.9% to $14.3 million in 2025, then fell by 4.35% to $13.7 million in 2026.
  • According to Business Quant data, Intangibles over the past three periods came in at $13.7 million, $14.3 million, and $14.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.